---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000004"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:45:34.527662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023

## Summary
- Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.
- Cash, cash equivalents and marketable securities $217.0M; runway into at least 2H 2026.
- TP-03 NDA accepted; PDUFA target action date August 25, 2023 for Demodex blepharitis.
- Completed enrollment of Ersa Phase 2a (MGD); topline data expected H2 2023.
- Initiated Galatea Phase 2a trial of TP-04 for rosacea; Phase 1 safety supported progression.

## SEC filing metadata
- accession: 0001819790-23-000004
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/0001819790-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/tars-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000004
- JSON: https://secwatch.observer/filing/0001819790-23-000004.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000004.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported the full-year ended December 31, 2022 results: revenue $25.8 million.
  - Period: the full-year ended December 31, 2022
  - Revenue: $25.8 million
  - Result: reported results
  source text: blepharitis ● TP-03 Topline Phase 2a (Ersa) Meibomian Gland Disease ● Full-Year 2022 Financial Results • Full year TP-03 out-license revenue for greater China territory was $25.8 million, compared to $57.0 million in 2021 • Full year net loss was $62.1 million, compared to $13.8 million in 2021 • Full year research and development expenses were $42.6 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/0001819790-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.